vs

Side-by-side financial comparison of Arcturus Therapeutics Holdings Inc. (ARCT) and GREENPOWER MOTOR Co INC. (GP). Click either name above to swap in a different company.

GREENPOWER MOTOR Co INC. is the larger business by last-quarter revenue ($7.2M vs $7.2M, roughly 1.0× Arcturus Therapeutics Holdings Inc.). On growth, GREENPOWER MOTOR Co INC. posted the faster year-over-year revenue change (-11.5% vs -68.4%).

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

GreenPower Motor Company Inc. is a Canadian electric bus manufacturer and distributor in North America. The company fabricates multiple zero-emission models, including transit buses, school buses, and double decker buses. GreenPower headquarters are in Vancouver, British Columbia, with a sales office in Rancho Cucamonga, California; an assembly facility in Porterville, California; and a production facility in South Charleston, West Virginia. Its stock is traded on Nasdaq the United States.

ARCT vs GP — Head-to-Head

Bigger by revenue
GP
GP
1.0× larger
GP
$7.2M
$7.2M
ARCT
Growing faster (revenue YoY)
GP
GP
+56.9% gap
GP
-11.5%
-68.4%
ARCT

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ARCT
ARCT
GP
GP
Revenue
$7.2M
$7.2M
Net Profit
$-4.7M
Gross Margin
14.6%
Operating Margin
Net Margin
-65.6%
Revenue YoY
-68.4%
-11.5%
Net Profit YoY
3.1%
-2.1%
EPS (diluted)
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARCT
ARCT
GP
GP
Q4 25
$7.2M
Q3 25
$17.2M
Q2 25
$28.3M
Q1 25
$29.4M
Q4 24
$22.8M
$7.2M
Q3 24
$41.7M
$5.3M
Q2 24
$49.9M
$3.0M
Q1 24
$38.0M
Net Profit
ARCT
ARCT
GP
GP
Q4 25
Q3 25
$-13.4M
Q2 25
$-9.2M
Q1 25
$-14.1M
Q4 24
$-30.0M
$-4.7M
Q3 24
$-6.9M
$-4.7M
Q2 24
$-17.2M
$-5.4M
Q1 24
$-26.8M
Gross Margin
ARCT
ARCT
GP
GP
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
14.6%
Q3 24
8.6%
Q2 24
7.4%
Q1 24
Operating Margin
ARCT
ARCT
GP
GP
Q4 25
Q3 25
-96.3%
Q2 25
-41.0%
Q1 25
-57.3%
Q4 24
-146.7%
Q3 24
-25.8%
Q2 24
-42.4%
Q1 24
-80.0%
Net Margin
ARCT
ARCT
GP
GP
Q4 25
Q3 25
-78.4%
Q2 25
-32.4%
Q1 25
-47.9%
Q4 24
-131.8%
-65.6%
Q3 24
-16.6%
-87.9%
Q2 24
-34.5%
-179.8%
Q1 24
-70.5%
EPS (diluted)
ARCT
ARCT
GP
GP
Q4 25
Q3 25
$-0.49
Q2 25
$-0.34
Q1 25
$-0.52
Q4 24
$-1.10
$-0.17
Q3 24
$-0.26
$-0.18
Q2 24
$-0.64
$-0.21
Q1 24
$-1.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARCT
ARCT
GP
GP
Cash + ST InvestmentsLiquidity on hand
$230.9M
$621.1K
Total DebtLower is stronger
Stockholders' EquityBook value
$214.0M
$2.1M
Total Assets
$271.1M
$37.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARCT
ARCT
GP
GP
Q4 25
$230.9M
Q3 25
$180.4M
Q2 25
$196.5M
Q1 25
$216.9M
Q4 24
$237.0M
$621.1K
Q3 24
$237.2M
$116.9K
Q2 24
$260.3M
$528.3K
Q1 24
$288.4M
Stockholders' Equity
ARCT
ARCT
GP
GP
Q4 25
$214.0M
Q3 25
$224.6M
Q2 25
$231.1M
Q1 25
$233.8M
Q4 24
$241.0M
$2.1M
Q3 24
$261.9M
$4.2M
Q2 24
$258.6M
$8.6M
Q1 24
$264.0M
Total Assets
ARCT
ARCT
GP
GP
Q4 25
$271.1M
Q3 25
$282.3M
Q2 25
$309.3M
Q1 25
$331.8M
Q4 24
$344.1M
$37.4M
Q3 24
$370.7M
$39.4M
Q2 24
$388.6M
$43.5M
Q1 24
$418.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARCT
ARCT
GP
GP
Operating Cash FlowLast quarter
$-74.3M
$-1.1M
Free Cash FlowOCF − Capex
$-74.5M
FCF MarginFCF / Revenue
-1035.2%
Capex IntensityCapex / Revenue
3.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARCT
ARCT
GP
GP
Q4 25
$-74.3M
Q3 25
$-17.2M
Q2 25
$-5.8M
Q1 25
$-35.1M
Q4 24
$-284.0K
$-1.1M
Q3 24
$-23.8M
$-1.3M
Q2 24
$-30.1M
$-3.2M
Q1 24
$-5.6M
Free Cash Flow
ARCT
ARCT
GP
GP
Q4 25
$-74.5M
Q3 25
$-17.3M
Q2 25
Q1 25
$-35.3M
Q4 24
Q3 24
$-23.8M
Q2 24
$-30.5M
Q1 24
$-5.8M
FCF Margin
ARCT
ARCT
GP
GP
Q4 25
-1035.2%
Q3 25
-101.1%
Q2 25
Q1 25
-120.1%
Q4 24
Q3 24
-57.2%
Q2 24
-61.1%
Q1 24
-15.3%
Capex Intensity
ARCT
ARCT
GP
GP
Q4 25
3.2%
Q3 25
1.1%
Q2 25
0.0%
Q1 25
0.5%
Q4 24
0.0%
Q3 24
0.2%
Q2 24
0.7%
Q1 24
0.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons